Femasys is a biomedical company focused on transforming women’s healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc, a first and only non-surgical product for permanent birth control and FemaSeed, a first and only directed sperm delivery product for infertility treatment. Femasys’ FemVue product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician’s office setting.

Fengchao Pharmaceutical Technology (Shanghai) Co., Ltd., established on 2015-08-11, The scope of business includes engaging in medical technology,Biological Technology,Ecotechnology,Chemical Technology,New Material Technology,Technology development in the field of new energy technology,technical consulting,Technical Services,technology transfer,Industrial Investment.[Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. The company's lead product, the PLAC Test, measures Lp-PLA2 (lipoprotein-associated phospholipase A2) a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis, that cause the majority of cardiovascular events. The PLAC Test is the only blood test cleared by the FDA as an aid in assessing risk for coronary heart disease, and ischemic stroke associated with atherosclerosis.

Cryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. It operates through the following segments: Cellular Processing and Cryogenic Storage, and Prepacyte CB. The Cellular Processing and Cryogenic Storage segment focuses on the collection and preservation of umbilical cord blood and tissue stem cells for family use. The Prepacyte CB segment refers to the processing technology used to process umbilical cord blood stem cells. The company was founded in 1989 and is headquartered in Oldsmar, FL.

PROCREA BioSciences, Inc. is a private company headquartered in Mount-Royal, QC, Canada, that develops reproductive medicines.

Siemens Healthcare Diagnostics, Inc. engages in the vitro diagnostics. It provides healthcare professionals in hospital, reference, and physician office laboratories and point-of-care settings with the vital information required to accurately diagnose, treat, and monitor patients. The company is headquartered in Tarrytown, NY.

Mochida Pharmaceutical is a drug manufacturing company. Their pharmaceutical business aims to develop and market a broad spectrum of innovative new drugs. They also offer creates skin care products for the general public, and these are supplied through pharmacies, and drugstores.

Sekisui Medical Co., Ltd., part of Sekisui Chemical Co., Ltd., is a company headquartered in Tokyo, Japan, that manufactures and markets in-vitro diagnostic substances and pharmaceutical products. Sekisui Chemical Co., Ltd. acquired Sekisui Medical Co., Ltd. from Daiichi Sankyo Co., Ltd. on October 02, 2006.

Minerva Biotechnologies develops cancer immunotherapies and cancer drugs to target 80% of solid tumors and to prevent cancer metastasis. Its stem cell technology could transform the field of regenerative medicine. It discovered that cancer cells are healthy cells that are being reprogrammed back to a stem cell state. It is also the first company to generate human naïve state pluripotent stem cells using a single, naturally occurring human stem cell growth factor. These earlier stem cells have a clean slate and are more easily directed to develop into functional mature cells, which could be used for transplant. It was founded in 1999 and is headquartered in Waltham, Massachusetts.

Celmatix is a next-generation women’s health company. They focus on reproductive health and fertility. Through their platform, they have amassed the largest structured dataset on ovarian health and outcomes in the world.

Igenomix SL is a biotechnology services company. It is engaged in providing non-invasive prenatal test, carrier genetic test, preimplantation diagnosis, sperm aneuploidy test, and endometrial receptivity array services. The company was founded by Carlos Simon Valles in 1996 and is headquartered in Paterna, Spain.

Beijing Angke Future Medical Equipment Co., Ltd., established on 2018-03-20, Business scope includes sales of Class I medical devices,Class II medical device,Professional setting,General Equipment,Chemical Products(Free of dangerous chemicals and precursor drugs);Medical Research and Experimental Development;technology development,technical consulting,technology transfer,Technical Services,Technology Promotion;Economic and Trade Consulting;Conference Services;Undertake exhibition and display activities;Import and export,Agent import and export,Technology Import and Export;Sales of Class III Medical Devices.(Enterprises independently choose operating projects according to law,Carry out business activities;Sales of Class III medical devices and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Manufactures in-vitro diagnostic substances

Xi'an Meijiajia Medical Technology Co., Ltd., established on 1998-03-04, Business scope includes general items:Production of Class I Medical Devices;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class I Medical Devices;Refrigeration,Air Conditioning Equipment Manufacturing;Sales of Class II Medical Devices;Special Equipment Repair;Sales of hygiene products and single-use medical products;Retailing of computer software, hardware and auxiliary equipment;Manufacturing of special equipment(Manufacture of licensed professional equipment not included);software development;Network and Information Security Software Development;Professional cleaning,to clean,Disinfection service;Glass fiber and product manufacturing;Glass fiber and product sales.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Production of Class II Medical Devices;Import and export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.